In Vivo Radical-Responsive Polymer Networks for Targeted Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current targeted drug delivery methods face challenges in specificity and sensitivity, particularly for conditions like traumatic brain injury, where tumors do not evenly express surface cell receptors, leading to off-target dumping and limited therapeutic efficacy, and there are no fully restorative interventions for secondary injuries.

Innovation Solution

A biocompatible conjugate that reacts with free radicals to form a cross-linked polymer network at injury sites, allowing localized delivery and sustained presentation of therapeutic agents, using polymers like PEG with functional groups that polymerize in response to abnormal radical levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If ligand-based targeted delivery is used to deliver therapeutics to tumor cells, then specificity to target cells is improved, but off-target dumping occurs due to heterogeneous receptor expression and limited therapeutic efficacy

Engineering Contradiction:

Improvetargeting specificityVSAvoidoff-target dumping

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of endogenously produced free radicals (which cause tissue damage) into a beneficial trigger for therapeutic activation. The biomaterial remains inert during circulation but activates polymerization specifically at injury sites where free radicals are abundant, thereby converting a harmful byproduct of injury into a useful signaling mechanism for targeted drug release.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The system uses the body's own free radicals at the injury site to trigger therapeutic activation without requiring external control mechanisms. The biomaterial autonomously responds to the chemical environment at the target site, eliminating the need for complex external triggering systems and reducing off-target effects.

Inventive Principle:

Principle #25Self-service

2Reliability

If free radicals are used to trigger in vivo polymerization for targeted delivery, then localized delivery at injury sites is improved, but radical-mediated damage to cells may occur

Engineering Contradiction:

Improvelocalized deliveryVSAvoidradical-mediated cell damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a biomaterial with free radical-responsive functional groups as an intermediary between the harmful free radicals and the therapeutic payload. This intermediary captures the radicals to trigger polymerization while the biomaterial structure protects cellular components from direct radical damage, effectively mediating the interaction between radicals and biological systems.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The system converts the harmful effect of free radicals (cell damage) into a beneficial trigger for therapeutic activation. By designing the biomaterial to respond to radical presence through polymerization, the harmful radicals become useful signals that initiate localized drug delivery without directly causing cellular damage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Quantity of substance

If current targeted delivery methods are used, then drug delivery to target tissue is achieved, but sensitivity and specificity are limited due to uneven receptor expression

Engineering Contradiction:

Improvedrug deliveryVSAvoidtargeting sensitivity

Core Design Contradiction:

Quantity of substanceVSMeasurement precision

Solution Approach 1:

The patent replaces the mechanical/chemical binding mechanism (ligand-receptor interaction) with a chemical polymerization mechanism triggered by free radicals. This substitution allows the system to bypass the limitations of receptor heterogeneity and achieve more precise targeting based on the universal presence of free radicals at injury sites.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The system changes the triggering parameter from receptor binding (which varies across tumor cells) to free radical concentration (which is consistently elevated at all injury sites). This parameter change enables uniform and sensitive detection of the target site regardless of cellular heterogeneity.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The conjugate effectively immobilizes therapeutics at injury sites, reducing radical damage and enhancing healing by localized delivery and sustained presentation, improving cell survival and healing processes.

Implementation Method 1

utilizing the radicals or stimuli generated during the injury to mediating the polymerization of a functionalized biomaterial

Methodology Applied

Scientific EffectFree radical polymerization: Photopolymerisation

Implementation Method 2

forming a cross-linked polymer network at injury sites, allowing localized delivery and sustained presentation of therapeutic agents

Methodology Applied

Scientific EffectCross-linking: Chemical Bonding

Data Source

PatentUS12419966B2In vivo radical-mediated polymerization for targeted delivery of trophic factors

Publication Date: 2025.09.23 RUTGERS THE STATE UNIV

AI summary

The present invention provides a biocompatible conjugate for treating a disease or an injury. The conjugate contains a polymer covalently linked to one or more moieties each containing a polymerizable functional group. The conjugate forms a cross-linked polymer network after being exposed to an elevated level of free radicals associated with the disease or injury.